How AstraZeneca's £300m Funding Supports UK Pharma Jobs

AstraZeneca will commit £300m (US$408m) to two UK sites after suspending major capital projects in 2025. The pharmaceutical company stopped investments due to pricing disputes and NHS drug availability concerns.

The funding will support existing facilities in Cambridge and Macclesfield. Cambridge receives the resumed £200m (US$272m) expansion that was paused, while Macclesfield gets an additional £100m (US$136m).

According to UK Prime Minister Keir Starmer, the investment will "future proof thousands of jobs". He told Parliament on 29 April that a "pharmaceutical arrangement we have struck with the United States" enabled the commitment.

Lab of the future planned

Chief Executive Officer Pascal Soriot says AstraZeneca will create a "lab of the future" at Macclesfield. The facility will use digital and data tools to speed up drug development.

"We would like to thank the British government for its efforts to improve access for patients, including four new approvals since the beginning of the year across the UK," he says.

"We look forward to further enhancing the access and the reimbursement environment and build a strong life sciences sector."

The Macclesfield site will create new scientific positions. Cambridge will receive data analysis and molecular science staff for its Rosalind Franklin office.

Government negotiations shift stance

AstraZeneca stopped work on the £200m (US$270.8m) Cambridge project in September 2025. The company also cancelled a £450m (US$612m) vaccine manufacturing investment at Speke in Merseyside.

According to AstraZeneca, government spending cuts prompted the pause despite months of talks. The new commitments could show the UK pharmaceutical climate has changed.

Susannah Streeter, Chief Investment Strategist at Wealth Club, called the development "super encouraging". She says: "It does seem as though there is a sense of momentum returning to the pharmaceutical industry in the UK."

Susannah described the Cambridge restart as "highly symbolic". She added that it "demonstrates how the government has been working hard behind the scenes to try and make the UK more attractive to big pharma."

Strong quarterly performance reported

AstraZeneca released its Q1 2026 earnings on 29 April showing 8% revenue growth to US$15.3bn. Operating profit rose 12% during the period.

Oncology treatments grew 16% while rare disease products increased 15%. Cancer drugs now represent nearly half of total company sales.

Pascal says in the earnings statement: "We delivered strong growth in Q1 2026, with total revenue above US$15bn, demonstrating our consistent commercial execution.

"We are advancing through our catalyst‑rich period, with positive readouts for four high-value Phase III programmes since our last quarterly results, including first pivotal data for two key new molecular entities (NMEs)."

According to AstraZeneca, several individual drugs could generate more than US$1bn in annual revenue by 2030. The company targets US$80bn in total sales by that year.

Pascal told the Q1 earnings call: "With a broad portfolio, a deep pipeline, and meaningful advances across multiple transformative technologies, we are well-positioned to extend growth beyond 2030."